Esperion says FDA won't commit to surrogate endpoint

Esperion Therapeutics Inc. (NASDAQ:ESPR) lost $4.40 (27%) to $11.78 in early after-hours trading Tuesday after it said FDA "did not provide clarity on a regulatory pathway" in dialogue with the

Read the full 308 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE